CLINICAL TRIALS PROFILE FOR LUMIFY

All Clinical Trials for lumify

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03782701 ↗	The Effect of Lumify™ Eyedrops on Eyelid Position	Completed	University of Miami	Phase 4	2019-06-18	The purpose of the research is to see if Lumify™ has an effect on eyelid position.
NCT03782701 ↗	The Effect of Lumify™ Eyedrops on Eyelid Position	Completed	Wendy Lee	Phase 4	2019-06-18	The purpose of the research is to see if Lumify™ has an effect on eyelid position.
NCT04007276 ↗	The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients	Not yet recruiting	Tulane University	Phase 4	2025-11-10	Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
NCT04024891 ↗	Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis	Completed	Ocuphire Pharma, Inc.	Phase 2	2019-08-13	The objectives of this study are: - To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis - To evaluate the safety of Nyxol - To evaluate the effect of Lumify® to suppress conjunctival hyperemia (redness) potentially associated with administration of Nyxol

Clinical Trial Conditions for lumify

Condition Name

Condition Name for lumify
Intervention	Trials
Ocular Redness	2
Glaucoma	1
Subconjunctival Hemorrhage	1
Glaucoma, Open-Angle	1

Condition MeSH

Condition MeSH for lumify
Intervention	Trials
Blepharoptosis	3
Dilatation, Pathologic	1
Ectropion	1
Glaucoma, Open-Angle	1

Clinical Trial Locations for lumify

Trials by Country

Trials by Country for lumify
Location	Trials
United States	21
Brazil	1

Trials by US State

Trials by US State for lumify
Location	Trials
Kentucky	4
Tennessee	2
North Carolina	2
Massachusetts	2
Kansas	2

Clinical Trial Progress for lumify

Clinical Trial Phase

Clinical Trial Phase for lumify
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
Phase 4	3

Clinical Trial Status

Clinical Trial Status for lumify
Clinical Trial Phase	Trials
Completed	4
Not yet recruiting	3
Recruiting	1

Clinical Trial Sponsors for lumify

Sponsor Name

Sponsor Name for lumify
Sponsor	Trials
Bausch & Lomb Incorporated	2
University of Louisville	1
University of Sao Paulo	1

Sponsor Type

Sponsor Type for lumify
Sponsor	Trials
Other	6
Industry	3

Last updated: April 27, 2026

What is the latest clinical and market outlook for Lumify (brimonidine tartrate ophthalmic)?

What is Lumify and who owns it?

Lumify is brimonidine tartrate ophthalmic solution indicated for treatment of ocular redness. In US commercial channels, it is marketed by Bausch + Lomb (brands and filings tied to the company’s ophthalmic portfolio).

What do the latest clinical trial updates show?

No verified, up-to-date clinical trial readout set (phase, status, results date, and sponsor) for Lumify (brimonidine tartrate ophthalmic solution) is identifiable from the information available in this prompt. A complete “clinical trials update” requires an external query to registries (eg, ClinicalTrials.gov) and a sponsor-specific sweep, which cannot be completed from the provided content.

How big is the Lumify market and what is the projection logic?

A complete market analysis and forward projection requires baseline market size, category growth drivers (OTC vs Rx mix where applicable, competitive set, pricing), and explicit forecast methodology inputs. Those inputs are not present in the provided content, so a numerically grounded projection cannot be produced without external sourced data.

What is the competitive landscape Lumify faces?

Lumify competes in topical ocular redness relief alongside other alpha-adrenergic agonist products (and in many geographies, “anti-redness” drops spanning prescription and nonprescription channels). A defensible market share model requires:

• brand-level sales or estimates,
• formulary and channel mix,
• competitor pricing and promotion,
• patient use rates and repeat behavior,
• channel-specific constraints (OTC vs Rx status varies by country and product).

No such quantified inputs are included in the prompt, so a structured competitive and forecast view cannot be completed to the required standard.

What does this mean for R&D and investment decisions now?

A correct actionable view for Lumify depends on:

• current phase/label expansion evidence,
• whether new trials are ongoing versus winding down,
• whether competitive entrants have meaningful differentiation (concentration, onset, duration, preservative profile, device/packaging),
• whether any patents or exclusivity milestones are material in the forecast window.

Those elements require registry and patent-landscape specifics not supplied in the prompt.

---

Key Takeaways

• A complete clinical trial update for Lumify requires verified current trial status and readouts by phase, date, and sponsor, which are not available in the prompt.
• A market analysis and projection requires quantified category and brand sales baselines, channel mix, competitive pricing, and growth assumptions, which are not available in the prompt.
• With only the prompt provided, producing a numeric projection or a trial-by-trial update would not meet a data-driven patent analyst standard.

---

FAQs

1. Is Lumify prescription or OTC?
   It is marketed for ocular redness relief in the US as an ophthalmic product; regulatory status can vary by country and product packaging.

2. What is the active ingredient in Lumify?
   Brimonidine tartrate ophthalmic solution.

3. What clinical endpoints matter most for ocular redness drops?
   Typically measures include ocular redness grading (eg, investigator- and/or subject-assessed scales), time to onset, and duration of effect, plus safety tolerability.

4. What drives growth for ocular redness brands?
   Usage frequency (situational redness), perceived speed of onset, duration of effect, tolerability, and channel availability.

5. What risks typically affect forecasts for ocular redness products?
   Generic and competitive pressure, labeling restrictions, channel shifts, and changes in payer or consumer preference.

---

References

[1] ClinicalTrials.gov. Brimonidine tartrate ophthalmic solution trials search results (query required).
[2] FDA. Lumify (brimonidine tartrate ophthalmic solution) labeling and regulatory history (product page required).
[3] Bausch + Lomb. Lumify product and corporate filings (source review required).